Cellectis shares are trading higher after the company announced that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors will be presented at SITC 2023.
Portfolio Pulse from Benzinga Newsdesk
Cellectis announced that pre-clinical data on MUC1-CAR T-cells, aimed at overcoming challenges of targeting solid tumors, will be presented at SITC 2023. This news has led to a rise in the company's share prices.
November 01, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis' announcement of presenting pre-clinical data on MUC1-CAR T-cells at SITC 2023 has led to a rise in its share prices.
The announcement of presenting pre-clinical data on MUC1-CAR T-cells, which are aimed at overcoming challenges of targeting solid tumors, is a positive development for Cellectis. This has led to increased investor confidence, resulting in a rise in the company's share prices.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100